MYDA Advisors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

MYDA Advisors’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-4,200	Closed	-$20K	–	151
2019 Q1	$20K	Buy	+4,200	New	+$11K	0.01%	113

Other funds holding SRNE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

MYDA Advisors's SRNE Position: Q2 2019 in Review

MYDA Advisors sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2019, closing a stake of 10,000 shares — an estimated $48K sold.

MYDA Advisors first reported a position in SRNE in Q4 2017 and held it in 3 quarters. The position peaked at $252K in Q2 2018. 83 funds tracked by Wall St. Rank hold SRNE as of Q2 2019.

MYDA Advisors reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
MYDA Advisors sold 10,000 Sorrento Therapeutics, Inc. shares in Q2 2019, an estimated $48K.
MYDA Advisors first reported a position in Sorrento Therapeutics, Inc. in Q4 2017 and held it in 3 quarters.
MYDA Advisors's Sorrento Therapeutics, Inc. position peaked at $252K in Q2 2018.
83 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2019.

Based on MYDA Advisors's 13F filing for Q2 2019, filed 13 Aug 2019.